Candel Therapeutics
CADL
82 hedge funds and large institutions have $120M invested in Candel Therapeutics in 2025 Q1 according to their latest regulatory filings, with 23 funds opening new positions, 40 increasing their positions, 11 reducing their positions, and 12 closing their positions.
264% more repeat investments, than reductions
Existing positions increased: 40 | Existing positions reduced: 11
92% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 12
66% more call options, than puts
Call options by funds: $4.4M | Put options by funds: $2.65M
15% more funds holding
Funds holding: 71 → 82 (+11)
2.6% more ownership
Funds ownership: 42.26% → 44.86% (+2.6%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
23% less capital invested
Capital invested by funds: $156M → $120M (-$36M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$25.8M |
| 2 |
BlackRock
New York
|
+$4.74M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$3.24M |
| 4 |
Marshall Wace
London,
United Kingdom
|
+$1.92M |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$1.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
B
Braidwell
Stamford,
Connecticut
|
-$13.9M |
| 2 |
BBA
Baker Bros. Advisors
New York
|
-$4.45M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$2.3M |
| 4 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$670K |
| 5 |
MS
Maven Securities
St Helier,
Jersey
|
-$449K |
CADL Hedge Fund Activity: Q1 2025 in Review
82 of the 7,459 institutional investors tracked by Wall St. Rank reported a position in Candel Therapeutics (CADL) for Q1 2025, worth a combined $120M — down 23% from $156M a quarter earlier.
Buyers outnumbered sellers: 23 funds opened new CADL positions and 12 closed out — a net gain of 11 holders — while 40 added to existing stakes and 11 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $25.8M. The largest seller was Braidwell, exiting entirely with an estimated $13.9M sold.
- 82 institutional investors held Candel Therapeutics (CADL) as of Q1 2025, up from 71 in Q4 2024.
- Funds reported $120M of Candel Therapeutics stock for Q1 2025, down 23% quarter-over-quarter.
- 23 funds opened new Candel Therapeutics positions in Q1 2025 and 12 closed out, a net change of +11 holders.
- The largest Candel Therapeutics buyer in Q1 2025 was Fidelity Investments, an estimated $25.8M added.
- The largest Candel Therapeutics seller in Q1 2025 was Braidwell, an estimated $13.9M sold.
Based on aggregated 13F filings for Q1 2025.